Capricor Therapeutics Inc. (CAPR)
$9.40
$0.12
(1.29%)
As on 04-Sep-2026 16:18EDT
Market cap
$547 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.7
-
Debt to Equity
0
-
Book Value
$4.2
-
EPS
$-2.4
-
Face value
--
-
Shares outstanding
58,138,989
10 Years Aggregate
CFO
$-108.12 Mln
EBITDA
$-159.26 Mln
Net Profit
$-142.21 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Capricor Therapeutics (CAPR)
| -67.4 | 123.8 | -66.0 | 49.7 | 12.5 | 13.4 | -13.0 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Capricor Therapeutics (CAPR)
| 109.1 | 179.8 | 26.7 | 31.7 | -14.6 | 168.0 | -68.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Capricor Therapeutics (CAPR)
|
9.4 | 546.5 | 0.0 | -129.4 | -- | -46.9 | -- | 2.4 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Capricor Therapeutics (CAPR)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the... United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California. Read more
-
Executive Chairman of the Board
Dr. Frank Isaac Litvack FACC, M.D.
-
Executive Chairman of the Board
Dr. Frank Isaac Litvack FACC, M.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Capricor Therapeutics (CAPR)
What is the current share price of Capricor Therapeutics Inc (CAPR) Today?
The share price of Capricor Therapeutics Inc (CAPR) is $9.40 (NASDAQ) as of 04-Sep-2026 16:18 EDT. Capricor Therapeutics Inc (CAPR) has given a return of 12.45% in the last 3 years.
What is the current PB & PE ratio of Capricor Therapeutics Inc (CAPR)?
Since, TTM earnings of Capricor Therapeutics Inc (CAPR) is negative, P/E ratio is not available.
The P/B ratio of Capricor Therapeutics Inc (CAPR) is 2.36 times as on 04-Sep-2026, a 56 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-13.42 |
4.61 |
2024 |
-12.01 |
3.34 |
2023 |
-5.88 |
5.79 |
2022 |
-3.35 |
8.24 |
2021 |
-3.53 |
2.26 |
What is the 52 Week High and Low of Capricor Therapeutics Inc (CAPR)?
The 52-week high and low of Capricor Therapeutics Inc (CAPR) are Rs 40.37 and Rs 2.96 as of 07-Sep-2026.
What is the market cap of Capricor Therapeutics Inc (CAPR)?
Capricor Therapeutics Inc (CAPR) has a market capitalisation of $ 547 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Capricor Therapeutics Inc (CAPR)?
Before investing in Capricor Therapeutics Inc (CAPR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.